Drug Trial Radar · NCT01949311
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Oct 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,733
Actual
Start
Oct 10, 2013
Primary completion
Jun 27, 2022
Study completion Jun 27, 2022
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Sep 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD). The secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment. Optional Sub-Study: The primary objective of the sub-study is to assess the safety of the new dupilumab drug product in adult patients with AD after switching from the current dupilumab drug product. The secondary objectives of the sub-study are to evaluate systemic exposure and immunogenicity of the new dupilumab drug product in adult patients with AD.
Conditions
- Atopic Dermatitis
Interventions
DupilumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 272 weeks
- OPTIONAL SUB-STUDY: Number of Adverse Events of Special Interest (AESIs) Through the Last Study Visit After Switching to the New Dupilumab Drug ProductTime frame: Up to 24 Weeks
Locations
432 sites in 28 countries. Site status is shown where the registry gives one.
Regeneron Study Site
Anniston, Alabama
Regeneron Study Site
Birmingham, Alabama
Regeneron Study Site 1
Birmingham, Alabama
Regeneron Study Site 2
Birmingham, Alabama
Regeneron Study Site 2
Phoenix, Arizona
Regeneron Study Site 3
Phoenix, Arizona
Regeneron Study Site 1
Phoenix, Arizona
Regeneron Study Site
Fort Smith, Arkansas
Regeneron Study Site
Rogers, Arkansas
Regeneron Study Site
Bakersfield, California
Regeneron Study Site
Clovis, California
Regeneron Study Site
Costa Mesa, California
Regeneron Study Site
Encinitas, California
Regeneron Study Site
Fremont, California
Regeneron Study Site
Lomita, California
Regeneron Study Site
Long Beach, California
Regeneron Study Site 1
Los Angeles, California
Regeneron Study Site 2
Los Angeles, California
Regeneron Study Site
Los Angeles, California
Regeneron Study Site
Oceanside, California
Regeneron Study Site
Orange, California
Regeneron Study Site
Rolling Hills Estates, California
Regeneron Study Site
San Diego, California
Regeneron Study Site 1
San Diego, California
Regeneron Study Site 2
San Diego, California
Regeneron Study Site
Santa Monica, California
Regeneron Study Site
Centennial, Colorado
Regeneron Study Site
Denver, Colorado
Regeneron Study Site
Denver, Colorado
Regeneron Study Site
Trumbull, Connecticut
Regeneron Study Site
Washington D.C., District of Columbia
Regeneron Study Site
Boca Raton, Florida
Regeneron Study Site
Clearwater, Florida
Regeneron Study Site
Fort Lauderdale, Florida
Regeneron Study Site 1
Jacksonville, Florida
Regeneron Study Site 2
Jacksonville, Florida
Regeneron Study Site
Lake Worth, Florida
Regeneron Study Site
Miami, Florida
Regeneron Study Site
Miami, Florida
Regeneron Study Site
Miami Lakes, Florida
Showing 40 of 432 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.